
|Articles|March 9, 2011
- December 2010
- Volume 4
- Issue 12
FDA Requests Label Change for Generic Docetaxel
Author(s)OBTN
The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.
Advertisement
The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel, which is currently being considered for FDA approval. The change is needed because Hospira’s version of the drug will be supplied in two 10-mg/mL vials, rather than in a single 20-mg/mL vial, which the FDA has said sanofi-aventis is permitted to use when selling Taxotere, its branded version of docetaxel.
Articles in this issue
almost 15 years ago
Medulloblastoma Subtypes Are Different Diseasesalmost 15 years ago
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myelomaalmost 15 years ago
FDA Considers Approval of Fusilev for Colorectal CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5



































